Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 322917
                    [Title] => Pinoy docs in most extensive anti-blood clot clinical trial
                    [Summary] => Boehringer-Ingelheim has launched the biggest ever thromboembolic disease clinical trial program. 


The trials under the umbrella name RE-VOLUTION and involving more than 27,000 patients worldwide, will investigate a novel oral direct thrombin inhibitor, dabigatran etexilate, researched and developed by the Germany-based pharmaceutical company to prevent and treat thromboembolic disease.


Dabigatran etexilate is a promising new oral direct thrombin inhibitor that specifically and reversibly inhibits thrombin, the key enzyme for blood clot formation. 


                    [DatePublished] => 2006-02-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 194372
                    [Title] => First treatment for acute ischaemic stroke launched
                    [Summary] => INGELHEIM, Germany – Boehringer Ingelheim has announced the European launch of Actilyse (altiplase) as the first and only treatment for acute ischaemic stroke after being approved by the European Commission.


The EC approved the use of the Actilyse treatment of selected patients with acute ischaemic stroke in the 0-3 hour window, based on the results of international clinical trials.


                    [DatePublished] => 2003-02-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DR. ANDREAS BARNER

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 322917
                    [Title] => Pinoy docs in most extensive anti-blood clot clinical trial
                    [Summary] => Boehringer-Ingelheim has launched the biggest ever thromboembolic disease clinical trial program. 


The trials under the umbrella name RE-VOLUTION and involving more than 27,000 patients worldwide, will investigate a novel oral direct thrombin inhibitor, dabigatran etexilate, researched and developed by the Germany-based pharmaceutical company to prevent and treat thromboembolic disease.


Dabigatran etexilate is a promising new oral direct thrombin inhibitor that specifically and reversibly inhibits thrombin, the key enzyme for blood clot formation. 


                    [DatePublished] => 2006-02-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 194372
                    [Title] => First treatment for acute ischaemic stroke launched
                    [Summary] => INGELHEIM, Germany – Boehringer Ingelheim has announced the European launch of Actilyse (altiplase) as the first and only treatment for acute ischaemic stroke after being approved by the European Commission.


The EC approved the use of the Actilyse treatment of selected patients with acute ischaemic stroke in the 0-3 hour window, based on the results of international clinical trials.


                    [DatePublished] => 2003-02-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Pinoy docs in most extensive anti-blood clot clinical trial

February 23, 2006 - 12:00am

Boehringer-Ingelheim has launched the biggest ever thromboembolic disease clinical trial program. The trials under the umbrella name RE-VOLUTION and involving more than 27,000 patients worldwide, will investigate...

Science and Environment

First treatment for acute ischaemic stroke launched

February 6, 2003 - 12:00am

INGELHEIM, Germany – Boehringer Ingelheim has announced the European launch of Actilyse (altiplase) as the first and only treatment for acute ischaemic stroke after being approved by the European Commission. The...

Science and Environment